A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

John K. Chan; William Brady; Bradley J. Monk; Jubilee Brown; Mark S. Shahin; Peter G. Rose; Jae Hoon Kim; Angeles Alvarez Secord; Joan L. Walker; David M. Gershenson

doi:10.1016/j.ygyno.2018.05.029

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

John K. Chan, William Brady, Bradley J. Monk, Jubilee Brown, Mark S. Shahin, Peter G. Rose, Jae Hoon Kim, Angeles Alvarez Secord, Joan L. Walker, David M. Gershenson

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

48 Citations (Scopus)

Abstract

Objectives: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. Methods: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%. Results: Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27–73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%–31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%–19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4–5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1). Conclusion: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.

Original language	English
Pages (from-to)	247-252
Number of pages	6
Journal	Gynecologic Oncology
Volume	150
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2018.05.029
Publication status	Published - 2018 Aug

Bibliographical note

Funding Information:
This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office ( CA 27469 ), the Gynecologic Oncology Group Statistical Office ( CA 37517 ), NRG Oncology ( 1 U10 CA180822 ) and NRG Operations ( U10CA180868 ), and Pfizer . The following Gynecologic Oncology institutions participated in this study: MD Anderson Cancer Center, UCSF-Mount Zion, Washington University School of Medicine, Duke University Medical Center, Abington Memorial Hospital, Cleveland Clinic Foundation, Seoul National University Hospital, University of Alabama at Birmingham, University of Colorado Cancer Center – Anschutz Cancer Pavilion, University of California Medical Center at Irvine-Orange Campus, Rush University Medical Center, University of Oklahoma Health Sciences Center, Case Western Reserve University, Carolinas Medical Center/Levine Cancer Institute, University of Iowa Hospitals and Clinics and Women and Infants Hospital. We would like to acknowledge The Fisher Family Foundation, Denise Cobb Hale, and Dr. John A. Kerner for their generous administrative research support.

Funding Information:
This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1 U10 CA180822) and NRG Operations (U10CA180868), and Pfizer. The following Gynecologic Oncology institutions participated in this study: MD Anderson Cancer Center, UCSF-Mount Zion, Washington University School of Medicine, Duke University Medical Center, Abington Memorial Hospital, Cleveland Clinic Foundation, Seoul National University Hospital, University of Alabama at Birmingham, University of Colorado Cancer Center – Anschutz Cancer Pavilion, University of California Medical Center at Irvine-Orange Campus, Rush University Medical Center, University of Oklahoma Health Sciences Center, Case Western Reserve University, Carolinas Medical Center/Levine Cancer Institute, University of Iowa Hospitals and Clinics and Women and Infants Hospital. We would like to acknowledge The Fisher Family Foundation, Denise Cobb Hale, and Dr. John A. Kerner for their generous administrative research support.

Publisher Copyright:
© 2018

All Science Journal Classification (ASJC) codes

Oncology
Obstetrics and Gynaecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ygyno.2018.05.029

Cite this

Chan, J. K., Brady, W., Monk, B. J., Brown, J., Shahin, M. S., Rose, P. G., Kim, J. H., Secord, A. A., Walker, J. L., & Gershenson, D. M. (2018). A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecologic Oncology, 150(2), 247-252. https://doi.org/10.1016/j.ygyno.2018.05.029

@article{c1accb2875954e979e1b53e951870329,

title = "A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)",

abstract = "Objectives: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. Methods: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%. Results: Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27–73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%–31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%–19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4–5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1). Conclusion: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.",

author = "Chan, {John K.} and William Brady and Monk, {Bradley J.} and Jubilee Brown and Shahin, {Mark S.} and Rose, {Peter G.} and Kim, {Jae Hoon} and Secord, {Angeles Alvarez} and Walker, {Joan L.} and Gershenson, {David M.}",

note = "Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office ( CA 27469 ), the Gynecologic Oncology Group Statistical Office ( CA 37517 ), NRG Oncology ( 1 U10 CA180822 ) and NRG Operations ( U10CA180868 ), and Pfizer . The following Gynecologic Oncology institutions participated in this study: MD Anderson Cancer Center, UCSF-Mount Zion, Washington University School of Medicine, Duke University Medical Center, Abington Memorial Hospital, Cleveland Clinic Foundation, Seoul National University Hospital, University of Alabama at Birmingham, University of Colorado Cancer Center – Anschutz Cancer Pavilion, University of California Medical Center at Irvine-Orange Campus, Rush University Medical Center, University of Oklahoma Health Sciences Center, Case Western Reserve University, Carolinas Medical Center/Levine Cancer Institute, University of Iowa Hospitals and Clinics and Women and Infants Hospital. We would like to acknowledge The Fisher Family Foundation, Denise Cobb Hale, and Dr. John A. Kerner for their generous administrative research support. Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1 U10 CA180822) and NRG Operations (U10CA180868), and Pfizer. The following Gynecologic Oncology institutions participated in this study: MD Anderson Cancer Center, UCSF-Mount Zion, Washington University School of Medicine, Duke University Medical Center, Abington Memorial Hospital, Cleveland Clinic Foundation, Seoul National University Hospital, University of Alabama at Birmingham, University of Colorado Cancer Center – Anschutz Cancer Pavilion, University of California Medical Center at Irvine-Orange Campus, Rush University Medical Center, University of Oklahoma Health Sciences Center, Case Western Reserve University, Carolinas Medical Center/Levine Cancer Institute, University of Iowa Hospitals and Clinics and Women and Infants Hospital. We would like to acknowledge The Fisher Family Foundation, Denise Cobb Hale, and Dr. John A. Kerner for their generous administrative research support. Publisher Copyright: {\textcopyright} 2018",

year = "2018",

month = aug,

doi = "10.1016/j.ygyno.2018.05.029",

language = "English",

volume = "150",

pages = "247--252",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "2",

}

Chan, JK, Brady, W, Monk, BJ, Brown, J, Shahin, MS, Rose, PG, Kim, JH, Secord, AA, Walker, JL & Gershenson, DM 2018, 'A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)', Gynecologic Oncology, vol. 150, no. 2, pp. 247-252. https://doi.org/10.1016/j.ygyno.2018.05.029

TY - JOUR

T1 - A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma

T2 - An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

AU - Chan, John K.

AU - Brady, William

AU - Monk, Bradley J.

AU - Brown, Jubilee

AU - Shahin, Mark S.

AU - Rose, Peter G.

AU - Kim, Jae Hoon

AU - Secord, Angeles Alvarez

AU - Walker, Joan L.

AU - Gershenson, David M.

N1 - Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office ( CA 27469 ), the Gynecologic Oncology Group Statistical Office ( CA 37517 ), NRG Oncology ( 1 U10 CA180822 ) and NRG Operations ( U10CA180868 ), and Pfizer . The following Gynecologic Oncology institutions participated in this study: MD Anderson Cancer Center, UCSF-Mount Zion, Washington University School of Medicine, Duke University Medical Center, Abington Memorial Hospital, Cleveland Clinic Foundation, Seoul National University Hospital, University of Alabama at Birmingham, University of Colorado Cancer Center – Anschutz Cancer Pavilion, University of California Medical Center at Irvine-Orange Campus, Rush University Medical Center, University of Oklahoma Health Sciences Center, Case Western Reserve University, Carolinas Medical Center/Levine Cancer Institute, University of Iowa Hospitals and Clinics and Women and Infants Hospital. We would like to acknowledge The Fisher Family Foundation, Denise Cobb Hale, and Dr. John A. Kerner for their generous administrative research support. Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office (CA 27469), the Gynecologic Oncology Group Statistical Office (CA 37517), NRG Oncology (1 U10 CA180822) and NRG Operations (U10CA180868), and Pfizer. The following Gynecologic Oncology institutions participated in this study: MD Anderson Cancer Center, UCSF-Mount Zion, Washington University School of Medicine, Duke University Medical Center, Abington Memorial Hospital, Cleveland Clinic Foundation, Seoul National University Hospital, University of Alabama at Birmingham, University of Colorado Cancer Center – Anschutz Cancer Pavilion, University of California Medical Center at Irvine-Orange Campus, Rush University Medical Center, University of Oklahoma Health Sciences Center, Case Western Reserve University, Carolinas Medical Center/Levine Cancer Institute, University of Iowa Hospitals and Clinics and Women and Infants Hospital. We would like to acknowledge The Fisher Family Foundation, Denise Cobb Hale, and Dr. John A. Kerner for their generous administrative research support. Publisher Copyright: © 2018

PY - 2018/8

Y1 - 2018/8

N2 - Objectives: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. Methods: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%. Results: Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27–73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%–31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%–19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4–5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1). Conclusion: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.

AB - Objectives: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. Methods: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%. Results: Of 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27–73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%–31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%–19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4–5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1). Conclusion: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.

UR - http://www.scopus.com/inward/record.url?scp=85048507153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048507153&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2018.05.029

DO - 10.1016/j.ygyno.2018.05.029

M3 - Article

C2 - 29921512

AN - SCOPUS:85048507153

SN - 0090-8258

VL - 150

SP - 247

EP - 252

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this